The impact of renin-angiotensin-aldosterone system blockade on contrast-induced nephropathy: A meta-analysis of 12 studies with 4,493 patients

Cardiology (Switzerland)

Volumn 130, Issue 1, 2015, Pages 4-14

  Jo, Sang Ho ^a   Lee, Joo Myung ^b   Park, Jonghanne ^b   Kim, Hyo Soo ^b,c  

^a Hallym University   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Angiotensin; Contrast media; Kidney; Meta analysis; Renin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CAPTOPRIL; DIATRIZOATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; IODIXANOL; IOHEXOL; IOPROMIDE; IOXAGLIC ACID; MEGLUMINE; PERINDOPRIL; QUINAPRIL; RAMIPRIL; CONTRAST MEDIUM;

ARTICLE; CHRONIC KIDNEY DISEASE; COMPARATIVE STUDY; CONTRAST INDUCED NEPHROPATHY; DATA EXTRACTION; DATA SYNTHESIS; DRUG EFFECT; HUMAN; META ANALYSIS; MORBIDITY; PRIORITY JOURNAL; QUALITY CONTROL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTEMATIC REVIEW; ACUTE KIDNEY INJURY; CHEMICALLY INDUCED; DRUG EFFECTS;

ACUTE KIDNEY INJURY; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CONTRAST MEDIA; HUMANS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84927698650     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000366473     Document Type: Article

References (33)

1. Gupta RK, Kapoor A, Tewari S, Sinha N, Sharma RK: Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Indian Heart J 1999; 51: 521-526.
2. Duan SB, Zhou XR, Pemg YM, Liu FY, Zhuo L, Li J, Chen YY, Xia YC: Prevention of radiocontrast-media-induced nephrotoxicity by perindopril and amlodipine in humans. China J Mod Med 2003; 13: 32-36.
3. Toprak O, Cirit M, Bayata S, Yesil M, Aslan SL: The effect of pre-procedural captopril on contrast-induced nephropathy in patients who underwent coronary angiography (in Turkish). Anadolu Kardiyol Derg 2003; 3: 98-103.
4. Toprak O, Cirit M, Bayata S, Yesil M, Aslan SL: The effect of captopril on contrast-induced nephropathy in diabetic patients. Kidney Blood Press Res 2004; 27 411.
5. Hashemi M, Kharazi A, Shahidi S: Captopril for prevention of contrast-induced nephropathy in patients undergoing coronary angioplasty: a double-blind placebo controlled clinical trial. J Res Med Sci 2005; 10: 305-308.
6. Cirit M, Toprak O, Yesil M, Bayata S, Postaci N, Pupim L, Esi E: Angiotensin-converting enzyme inhibitors as a risk factor for contrastinduced nephropathy. Nephron Clin Pract 2006; 104:c20-c27.
7. Kiski D, Stepper W, Brand E, Breithardt G, Reinecke H: Impact of renin-angiotensin-aldosterone blockade by angiotensin-converting enzyme inhibitors or at-1 blockers on frequency of contrast medium-induced nephropathy: a post-hoc analysis from the Dialysis-versus-Diuresis (DVD) trial. Nephrol Dial Transplant 2010; 25: 759-764.
8. Rim MY, Ro H, Kang WC, Kim AJ, Park H, Chang JH, Lee HH, Chung W, Jung JY: The effect of renin-angiotensin-aldosterone system blockade on contrast-induced acute kidney injury: a propensity-matched study. Am J Kidney Dis 2012; 60: 576-582.
9. Baris N, Ozpelit E, Dogan NB, Kangul H, Gul S, Akdeniz B, Guneri S: The effects of chronic usage of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on contrast-induced nephropathy in low-risk patients. Anadolu Kardiyol Derg 2013; 13: 245-250.
10. Rosenstock JL, Bruno R, Kim JK, Lubarsky L, Schaller R, Panagopoulos G, DeVita MV, Michelis MF: The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy. Int Urol Nephrol 2008; 40: 749-755.
11. Li XM, Cong HL, Li TT, He LJ, Zhou YJ: Impact of benazepril on contrast-induced acute kidney injury for patients with mild to moderate renal insufficiency undergoing percutaneous coronary intervention. Chin Med J 2011; 124: 2101-2106.
12. Shemirani H, Pourrmoghaddas M: A randomized trial of saline hydration to prevent contrast-induced nephropathy in patients on regular captopril or furosemide therapy undergoing percutaneous coronary intervention. Saudi J Kidney Dis Transplant 2012; 23: 280-285.
13. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary Control Clin Trials 1996; 17: 1-12.
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
15. McCullough PA: Contrast-induced acute kidney injury. J Am Coll Cardiol 2008; 51: 1419-1428.
16. Li X, Li T, Fu N, Hu Y, Cong H: Is angiotensin-converting enzyme inhibitor appropriate for contrast-induced nephropathy A metaanalysis about this field. Int J Cardiol 2012; 155: 486-488.
17. Li X, Li T, Cong H: Is angiotensin-converting enzyme inhibitor a contraindication for contrast-induced nephropathy prophylaxis A review about its paradox. Cardiovasc Ther 2012; 30: 273-276.
18. Patel K, King CA, Jovin IS: Angiotensin-converting enzyme inhibitors and their effects on contrast-induced nephropathy after cardiac catheterization or percutaneous coronary intervention. Cardiovasc Revasc Med 2011; 12: 90-93.
19. Onuigbo MA: Can ACE inhibitors and angiotensin receptor blockers be detrimental in CKD patients Nephron Clin Prac 2011; 118:c407-c419.
20. Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S: Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ 2013; 346:e8525.
21. Ahmed AK, Kamath NS, El Kossi M, El Nahas AM: The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant 2010; 25: 3977-3982.
22. Jones CA, Krolewski AS, Rogus J, Xue JL, Collins A, Warram JH: Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause Kidney Int 2005; 67: 1684-1691.
23. Suissa S, Hutchinson T, Brophy JM, Kezouh A: Ace-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int 2006; 69: 913-919.
24. Heyman SN, Brezis M, Reubinoff CA, Greenfeld Z, Lechene C, Epstein FH, Rosen S: Acute renal failure with selective medullary injury in the rat. J Clin Invest 1988; 82: 401-412.
25. Brewster UC, Perazella MA: The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 2004; 116: 263-272.
26. Fleming I, Kohlstedt K, Busse R: New fACEs to the renin-angiotensin system. Physiology (Bethesda) 2005; 20: 91-95.
27. Munzel T, Keaney JF Jr: Are ACE inhibitors a 'magic bullet' against oxidative stress Circulation 2001; 104: 1571-1574.
28. Holtkamp FA, de Zeeuw D, Thomas MC, Cooper ME, de Graeff PA, Hillege HJ, Parving HH, Brenner BM, Shahinfar S, Lambers Heerspink HJ: An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in longterm renal function. Kidney Int 2011; 80: 282-287.
29. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS: Renal considerations in angiotensin-converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 2001; 104: 1985-1991.
30. Lee HT, Kim M, Kim J, Kim N, Emala CW: TGF-1 release by volatile anesthetics mediates protection against renal proximal tubule cell necrosis. Am J Nephrol 2007; 27: 416-424.
31. Junaid A, Rosenberg ME, Hostetter TH: Interaction of angiotensin II and TGF-1 in the rat remnant kidney. J Am Soc Nephrol 1997; 8: 1732-1738.
32. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX: 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Catheter Cardiovasc Interv 2013; 82:E1-E27.
33. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D: Guidelines on myocardial revascularization. Eur Heart J 2010; 31: 2501-2555.